Compound ID | 133

Update compound information

TD-1607

Class: Glycopeptide-cephalosporin heterodimer

Spectrum of activity: Gram-positive
Details of activity: Acute bacterial skin and skin structure infections (ABSSSI), hospital-acquired pneumonia/ ventilator-associated pneumonia, bacteremia
Institute where first reported: Theravance Biopharma, USA
Year first mentioned: 2010
Highest developmental phase: Phase 1 (NCT01949103)
Development status: Active
External links:
Citations:
  • https://adisinsight.springer.com/drugs/800018077
  • https://clinicaltrials.gov/ct2/show/NCT01949103
  • https://www.theravance.com/our-pipeline
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120311/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.